• Caris Life Sciences announced Nov. 11, 2026, that enrollment had begun in a study testing ChromoSeq as an alternative to conventional testing.
• First patients enrolled in late September 2026; approximately 300 adults with myeloid malignancies will enroll across multiple U.S. institutions through July 2027.
• The study will generate prospective results comparing the sequencing workflow with conventional testing for risk classification, ease of use and turnaround time.
• ChromoSeq combines whole-genome and whole-transcriptome sequencing in one report, aiming to simplify testing that currently requires multiple laboratory workflows.
• Enrollment follows MolDX approval, supporting efforts to expand sequencing access and build clinical evidence for broader adoption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.